Industry-supported CME received a merciless drubbing today at the Senate Hearing. I'll report some of my observations tomorrow, but for now I wanted to post some of the written testimony, since it may not be available from the Senate for another week or so.
--Steve Nissen's Testimony
--Eric Campbell's Testimony
--ACCME (Murray Kopelow) Testimony
--Thomas Stossel's Testimony
I'll post others as I receive them.
skip to main |
skip to sidebar
"This is one of the most concise and practical guides that I have ever seen." - Christina M. Delos Reyes, MD
Click the book cover for more information
Keeping Psychiatry Honest Since 2007
New Book! Addiction Treatment—A Carlat Guide
"This is one of the most concise and practical guides that I have ever seen." - Christina M. Delos Reyes, MD
Earn CME Credits Online with The Carlat Psychiatry Report
Subscribe to our RSS Feed!Buy the Carlat Medication Fact Book
Click the book cover for more information
About Dr. Carlat
I am a psychiatrist in Newburyport, Massachusetts and an Associate Clinical Professor of Psychiatry at Tufts Medical School (but note that the opinions expressed in this blog are not those of Tufts). I graduated from the psychiatric residency at Massachusetts General Hospital in 1995, and am the founder and publisher of three CME newsletters: The Carlat Psychiatry Report, The Carlat Child Psychiatry Report, and The Carlat Addiction Treatment Report.
Psychiatry Links
Pharma-Skeptical Sites
Pharma-Friendly Sites
CME Sites
Blog Archive
-
▼
2009
(92)
-
▼
July
(13)
- Senate CME Hearing: Impressions, More Links
- Senate Hearing on CME: Links to Testimony
- Live Blogging the Senate Hearing on Industry-Funde...
- Senator Kohl Targets Commercial CME in Hearing Tom...
- ACRE Meeting: Welcome to Anger Village
- ACRE Charter Meeting's Unofficial Press Packet
- New ACCME Report: Commercial CME Support Enters Fr...
- ACRE: Academics Craving Reimbursement for Everything
- Note to Emory: A Modest Proposal
- Current Psychiatry Publishes Covert Industry Ad
- "Old Friends" Battle it out Over DSM-V Psychosis
- The DSM-V Armageddon, Part 2
- Prescription Data-Mining is Getting Battered in Court
-
▼
July
(13)
Labels
- 12-step programs (1)
- AA (1)
- AARP (1)
- Abilify (6)
- ACCME (16)
- ACCME report (1)
- ACRE (3)
- Addyi (1)
- ADHD (5)
- Advertising (2)
- Akathisia (2)
- Alan Schatzberg (6)
- Alcoholics Anonymous (1)
- Alison Bass (1)
- Alkermes Pharmaceuticals (1)
- Allen Frances (2)
- Alliance for CME (2)
- Alzheimer's disease (1)
- AMA (4)
- Amen Clinics (2)
- American Academy of Allergy (1)
- American Academy of Orthopaedic Surgeons (1)
- American Board of Medical Specialties (1)
- American College of Cardiology (1)
- American Journal of Psychiatry (2)
- American Medical Association (3)
- American Psychiatric Association (8)
- American Psychiatric News (2)
- American Society of Hypertension (1)
- Anatomy of an Epidemic (1)
- Andrew Wilner (1)
- AndroGel (1)
- Angell (1)
- Antidepressants (3)
- Antidote (1)
- antipsychotics (4)
- Anxiety disorders (1)
- APA (4)
- APA election (2)
- Aplenzin (1)
- Appelbaum (1)
- aripiprazole (1)
- Assurex (1)
- Asthma and Immunology (1)
- Astra Zeneca (11)
- Atlantic Magazine (1)
- BBC (1)
- Behrman (1)
- Bernard Carroll (1)
- bifeprunox (2)
- Billy Rubin's Blog (1)
- binge eating disorder (1)
- BIO 2008 (1)
- Bioethics (1)
- Biomarkers (2)
- bipolar depression (1)
- bipolar disorder (1)
- Blogging (1)
- BlueSpark (1)
- BMJ (1)
- book review (1)
- Boston Globe (3)
- Boston University (1)
- Brain Devices (1)
- Brand(x) (1)
- Bremmer (1)
- Brigham and Woman's Hospital (1)
- Brintellix (1)
- Bristol-Myers Squibb (8)
- British Medical Journal (3)
- bupropion (1)
- BusinessWeek (3)
- CAFE study (1)
- Califf (1)
- California Academy of Family Physicians (1)
- Canadian Medical Association (1)
- Carl Elliott (1)
- Carlat CME Institute (1)
- CATIE trial (1)
- CATR (1)
- CE Measure (1)
- CECentral (1)
- CEJA (5)
- Center for Medicine in the Public Interest (1)
- Cephalon (1)
- Cervero (2)
- Chantix (1)
- Charles Ornstein (1)
- Chicago Tribune (1)
- child psychiatry (1)
- Clawsen (1)
- CME (5)
- CME LLC (1)
- CME Outfitters (1)
- CME Peer Review (2)
- CME Reform (1)
- CME Rogue's Gallery (1)
- CME Zone (2)
- CNS News (1)
- CNS Spectrums (4)
- Coalition for Healthcare Communication (1)
- Colbert (1)
- commercial bias (24)
- Commercial Bias Inventory (1)
- Commercial Support Free CME (1)
- Comparative effectiveness research (1)
- Conflicts of Interest (7)
- Connors (1)
- continuing medical education (1)
- Contrave (1)
- Corruption (2)
- Council of Medical Specialty Societies (1)
- Counter-detailing (2)
- CS2day (1)
- Current Psychiatry (6)
- CVS Caremark (2)
- Cymbalta (3)
- Dallas Leipzig International Valve 2010 (1)
- data-mining (2)
- Dave Davies (1)
- David Kupfer (1)
- David Polly (1)
- Delaware Media Group (1)
- depression (2)
- Depression Central (1)
- DesignWrite (5)
- Deval Patrick (1)
- DeVane (1)
- Devices (1)
- Direct to consumer ads (1)
- dirty thirty (1)
- disclosure (1)
- Dollars for Docs (1)
- Donna Beales (1)
- Donna Norris (1)
- Doug Bremner (1)
- Dowden Health Media (2)
- Dr. Drug Rep (1)
- Dr. RW (1)
- drug companies (1)
- drug reps (3)
- Drug-drug interactions (1)
- DSM-V (6)
- DuBuske (1)
- EEG (1)
- Effexor (4)
- Eli Lilly (16)
- Emory University (6)
- EMSAM (1)
- Epocrates (1)
- Ethics Policies (1)
- Fauber (1)
- FDA (7)
- fibromyalgia (1)
- Flibanserin (1)
- Forest Laboratories (2)
- Free samples (1)
- free speech (1)
- Fresh air (1)
- Frontline (1)
- Fugh-Berman (5)
- Functional neuroimaging (1)
- Furious Seasons (1)
- Gardiner Harris (2)
- Gawande (1)
- generics (1)
- GeneSight (2)
- Genetic Testing (1)
- genetics (1)
- ghostwriting (5)
- gift ban (3)
- GlaxoSmithKline (4)
- Goldberg (2)
- Goodwin (5)
- Goozner (1)
- Governor Deval Patrick (1)
- Grassley (8)
- Great Britain (1)
- Greater Boston (1)
- greed (1)
- Harvard Medical School (1)
- Haymarket Medical (1)
- Health Affairs (1)
- Health care reform (1)
- Health Care Renewal (1)
- HealthGrades (1)
- Heart Rhythm Society (1)
- hired gun (4)
- Hormone replacement therapy (1)
- hospitality (1)
- HSDD (1)
- Hypoactive Sexual Desire Disorder (1)
- i3 CME (4)
- IMS (2)
- In Her Wake (1)
- Indianapolis Star (2)
- industry-free CME (4)
- industry-funded CME (11)
- Insel (2)
- Institute for Continuing Healthcare (1)
- Institute of Medicine (1)
- Invega (2)
- iPhone (1)
- IRINE (1)
- Ivan Goldberg (1)
- JAMA (5)
- James Stein (1)
- Janssen (1)
- Jazz Pharmaceuticals (2)
- Jeffrey Flier (1)
- Jerry Avorn (1)
- John Kelsoe (1)
- John Russell (1)
- Johns Hopkins (2)
- Johnson and Johnson (1)
- Joseph Biederman (4)
- Journal of Clinical Psychiatry (4)
- Judith Graham (1)
- key opinion leaders (1)
- Kickbacks (1)
- Kulongoski (2)
- Latuda (1)
- legal consultation (1)
- Letters and Science (1)
- Lexapro (1)
- Liebowitz (1)
- Lighthouse Learning (1)
- Lisa Cosgrove (1)
- Lizbeth Kowalszyk (1)
- LLC (1)
- Lurasidone (2)
- Luvox CR (1)
- Luvox SR (1)
- M/C Communications (1)
- Macy Foundation (2)
- major depressive disorder (1)
- Manhattan Research (1)
- Marcia Angell (1)
- Marketing tactics (1)
- Martha Rosenberg (1)
- Martin Samuels (1)
- Massachusetts General Hospital (4)
- Massachusetts gift ban (11)
- McAllen (1)
- McCain (1)
- McGeeney (1)
- McMahon Publishing Group (2)
- MDDScore (1)
- Med Page Today (1)
- Medbribe (1)
- Medical Marketing and Media (1)
- Medical Meetings Magazine (3)
- Medical Societies (1)
- Medscape (11)
- Medtronic (2)
- Meghna Chakrabarti (1)
- Melody Peterson (1)
- Memorial Sloan-Kettering (2)
- Mental Health American (1)
- Merck (1)
- Michael First (1)
- Milwaukee Journal Sentinel (2)
- Mina Dulcan (1)
- Minh Uong (1)
- Mother Jones (1)
- Mukherjee (1)
- Nancy Rappaport (1)
- Natasha Singer (1)
- National Physician's Alliance (2)
- NEBA (1)
- Nemeroff (15)
- Nesi (1)
- Neuroinvestment (1)
- Neuroscience education insttitute (1)
- neuroscienceCME (1)
- New Hampshire (2)
- New York State Assembly (1)
- New York Times (5)
- New York Times Magazine (3)
- New Yorker (1)
- Niravam (1)
- Nissen (1)
- Notes from RW (1)
- Novartis (1)
- Nuvigil (1)
- Obama (2)
- Off-label promotion (1)
- On Point (1)
- Open Payments (1)
- opiates (1)
- Oransky (1)
- Oregon (3)
- Oregon Academy of Family Physicians (1)
- Orexigen (1)
- Otsuka (2)
- Pain TV (1)
- Parry (1)
- Partners (2)
- Patent Extenders (1)
- Pathophilia (2)
- Patient Priming (1)
- Paul Simon (1)
- Paul Thacker (1)
- Pew (1)
- Pfizer (5)
- pharma marketing blog (1)
- Pharmaceutical marketing (3)
- pharmacogenetics (1)
- Pharmed Out (2)
- PhRMA code (1)
- Physi (1)
- Physician disclosure (1)
- Physician payments (4)
- Physician Payments Sunshine Act (5)
- Pies (1)
- Placebo controlled trial (3)
- Placebo Journal Blog (1)
- podcast (1)
- Poison Pills (1)
- Policy and Medicine (2)
- practice guidelines committee (1)
- premarin (1)
- Prempro (2)
- prescription data-mining (5)
- Prescription project (1)
- prescriptive privileges (1)
- Pri-Med (1)
- Primary Psychiatry (2)
- Primedia Healthcare (1)
- Pristiq (3)
- PRMS (1)
- Product theaters (1)
- Professional Medical Associations (1)
- promotional speakers (3)
- ProPublica (5)
- Psychiatric Times (3)
- Psychiatry websites (2)
- psychologists (3)
- psychosis (1)
- psychotherapy (2)
- Psynomics (1)
- PV Updates (1)
- QuantiaMD (1)
- Radio Boston (1)
- Rajnish Mago (1)
- Reed Elsevier (1)
- Relman (1)
- Remission (1)
- Reporting on Health (1)
- Research (2)
- Reviews of websites (2)
- Ridge Diagnostics (1)
- Robert DeLeo (1)
- Robert Freedman (1)
- Royal College of Physicians (1)
- Rozerem (1)
- sanofi aventis (1)
- SAPHRIS (2)
- Schatzberg (2)
- Schering-Plough (2)
- Schwarz Pharma (1)
- Schwitzer (1)
- seeding trials (1)
- Senate Aging Committee (2)
- Senate Finance Committee (1)
- Senator Herb Kohl (2)
- SentinelSource (1)
- Sepracor (1)
- Seroquel (11)
- Shahram Ahari (1)
- Sharfstein (1)
- Shire (4)
- Silenor (1)
- Simple and Practical Mental Health (1)
- SmithKline Beecham (1)
- Soltan (2)
- Solvay (3)
- Somaxon (1)
- SPECT (1)
- Spencer (1)
- Spielmans (1)
- Sprout Pharmaceuticals (1)
- Standards for Commercial Support (1)
- Stanford University (2)
- Stephen Stahl (3)
- Sternthal (1)
- Steve DiFillippo (2)
- Steven Stahl (1)
- stimulants (1)
- Stossel (1)
- Stowe (2)
- Strattera (1)
- Sunovion (2)
- super PACs (1)
- surveys (2)
- Symbyax (1)
- Takeda (1)
- Tamar Hosansky (1)
- testosterone (1)
- Thacker (1)
- The Carlat Addiction Treatment Report (1)
- The Carlat Medical Report (1)
- The Carlat Psychiatry Report (1)
- The Infinite Mind (4)
- The Psychiatrist's Program (2)
- Thomas Sullivan (1)
- Thought Broadcast (1)
- Tim Kuklo (1)
- TMS (1)
- Tom Ashbrook (1)
- Tom Sullivan (1)
- Transcranial Magnetic Stimulation (1)
- Tufts (1)
- Unbranded Doctor (1)
- University Diaries (1)
- University of Michigan (1)
- University of North Texas Health Science Center (1)
- University of Wisconsin (3)
- Verispan (1)
- Vermont (2)
- Vermont Psychiatric Association (1)
- Viibryd (1)
- vilazodone (1)
- Vioxx (1)
- Viracept (1)
- vortioxetine (1)
- Vox Medica (1)
- Vyvanse (2)
- Wall Street Journal Health Blog (1)
- Washington Post (1)
- Web Chat (1)
- WebMD (1)
- Website reviews (2)
- Whitaker (1)
- Wilens (1)
- William Carpenter (1)
- William Heisel (2)
- Wired magazine (1)
- Wisconsin Medical Society (1)
- Wood (1)
- Wyeth Pharmaceuticals (12)
- Zimmerman (1)
- Zyprexa (2)
2 comments:
Steve Nissen, Dr. Grandstander....don't think I can stomach watching. Sorry.
The hypocrisy of Dr. Nissen is simply breathtaking. He should disclose the amount of money that he has taken from industry and especially at those fancy association meeting symposia. He was one of the most over the top promoters of torcetrapib before that all came crashing down.
If he were really sincere, he would confess his sins and perhaps--like Dr. Carlat--make up for it. However, I would expect that he would rather sit on his horde and figure out how to angle for some big post at the FDA or CMS.
Post a Comment